Notably, compared with other TOP1 inhibitors, TLC388 exhibited a greater capacity to enhance STING phosphorylation in MSS-CRC cell lines (HT29 and CT26), which are characterized by low immunogenicity (Fig. 1H). Here, TOP1 is linked to colorectal carcinoma.